Business context and reporting period
Important entity mismatch: The supplied filing is BCTG Acquisition Corp.’s Form 10-Q, not a filing for Tango Therapeutics, Inc. It reports the quarter ended September 30, 2020, and the period from May 21, 2020 (inception) through September 30, 2020. BCTG was a blank-check company seeking a business combination, with an intended focus on biotechnology businesses in North America and Europe. It had not begun operating or generated revenue.
Financial results and position
- Revenue: None. BCTG stated it would not generate operating revenue before completing a business combination.
- Net loss: $52,390 for the quarter; $52,862 from inception through September 30. Inception-period expenses included $29,231 in general and administrative expenses and $35,491 in franchise taxes, partly offset by trust investment income.
- Cash flow: $89,281 used in operating activities and $168.4 million provided by financing activities from inception through September 30. Ending operating cash was $1.55 million.
- Assets and liquidity: Total assets were $168.4 million, including $166.8 million held in the trust account and $1.6 million in current assets. Working capital was approximately $1.5 million.
- Liabilities and equity: Total liabilities were $5.95 million, including $5.84 million in deferred underwriting commissions. Stockholders’ equity was $5.00 million; 15.74 million shares were classified as temporary equity due to possible redemption.
- Debt: The sponsor loan used for IPO costs was repaid in full on September 10, 2020; no working-capital loans were outstanding at quarter-end.
- Margins: Not meaningful for this pre-combination company with no operating revenue.
Material changes and unusual items
BCTG completed its IPO on September 8, 2020, selling 16.675 million public shares at $10 per share for $166.75 million gross proceeds. It also raised approximately $5.3 million in a sponsor private placement. The underwriters exercised the over-allotment option in full. Approximately $166.8 million was deposited in the trust account; IPO costs were approximately $9.6 million, including $5.8 million of deferred underwriting commissions payable only if a business combination closes. The filing provides no established prior-year comparable period because the company was newly formed in May 2020.
Outlook, risks, and contingencies
- Management believed available working capital and borrowing capacity would fund needs through the earlier of a business combination or one year from the filing. It planned to use funds for target identification, diligence, and transaction costs.
- The company had until September 8, 2022, to complete a business combination, absent an approved extension. If unsuccessful, it planned to redeem public shares and liquidate, subject to creditor claims and applicable law.
- The sponsor committed to purchase at least 2.5 million additional shares for $25 million in a private placement before, at, or after the business combination.
- Management said the specific impact of COVID-19 was not readily determinable; the financial statements included no related adjustments. Completion of a business combination was not assured. Insiders’ trust-protection indemnity may not be collectible.
- The company reported effective disclosure controls, no material change in internal control, no legal proceedings, and no off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm the filing’s registrant: the supplied document identifies BCTG Acquisition Corp. (ticker BCTG), not Tango Therapeutics, Inc.
- Verify the trust balance, redemption terms, and September 8, 2022 business-combination deadline against the correct filing and any subsequent amendments.
- Check whether the proposed $25 million sponsor share purchase occurred and whether a business combination was ultimately completed.
- Review subsequent filings for changes to liquidity, transaction costs, sponsor financing, or COVID-related disclosures.